Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.021753169504775502 | N/A |
Market Cap | $6.30M | N/A |
Shares Outstanding | 289.39M | 7.73% |
Employees | 0 | N/A |
Shareholder Equity | 6.79M | 7.46% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -1.22 | N/A |
P/S Ratio | 5.82 | N/A |
P/B Ratio | 0.93 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.5134 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $1.08M | N/A |
Earnings | -$3.49M | N/A |
EPS | -0.0178 | N/A |
Earnings Yield | -0.8168 | N/A |
Gross Margin | -0.4066 | N/A |
Operating Margin | -4.47 | N/A |
Net income margin | -3.22 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $6.91M | N/A |
Total Debt | $864.10K | N/A |
Cash on Hand | $1.86M | N/A |
Debt to Equity | 0.3372 | 62.84% |
Cash to Debt | $2.15 | -64.93% |
Current Ratio | 0.9057 | -67.97% |